Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    Hemopurifier Ebola Treatment Protocol Approved

    By Global Biodefense StaffJanuary 5, 2015
    Aethlon Hemopurifier Used for Ebola Treatment
    Share
    Facebook LinkedIn Reddit Email

    Aethlon Medical, Inc. last week announced they have received U.S. Food and Drug Administration (FDA) approval for a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier.

    In the treatment of viral pathogens, the Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.

    The approved Ebola treatment protocol allows for an investigational study to be conducted at up to 10 U.S. clinical sites, and up to 20 U.S. subjects may be enrolled to receive the treatment protocol.

    Patients who meet the enrollment criteria will receive a daily six to eight hour administration of Hemopurifier therapy until the point that Ebola viral load drops below 1000 copies/ml. The goal of the study is to standardize and evaluate the use of the Hemopurifier as supportive care in the treatment of Ebola virus disease.

    The Ebola treatment protocol resulted from the submission of a supplement to an Investigation Device Exemption (IDE) previously approved by FDA.  The supplement was entitled, “Treatment of Ebola Virus Disease (EVD) in Humans with the Aethlon Hemopurifier® Lectin Affinity Plasmapheresis Device.”

    Based on the previously approved IDE protocol, Aethlon is conducting a clinical feasibility study of Hemopurifier therapy in individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy.

    As the approved Ebola treatment protocol is a deviation from the HCV protocol, Aethlon was required to clearly distinguish data collected in the supplemental Ebola protocol study from data derived from the Company’s HCV trials.

    Capture of Ebola Viruses

    Aethlon previously reported that Hemopurifier therapy was successfully administered to a critically-ill Ebola patient at Frankfurt University Hospital in Germany. On November 14, 2014, the resulting Hemopurifier treatment data was presented at the American Society of Nephrology (ASN) Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital. Dr. Geiger reported that 242 million Ebola viruses were captured within the Hemopurifier during treatment, a number verified by a post-treatment elution protocol. The elution protocol has since been repeated, which resulted in second measurement of 253 million copies of Ebola virus captured within the Hemopurifier.

    Dr. Geiger also reported that the patient’s viral load prior to the administration of a single 6.5-hour Hemopurifier treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). A post-treatment viral load measurement was reported to be 1,000 copies/ml. The treatment was well tolerated with no adverse events reported.

    At the time of treatment, the Ebola patient was unconscious and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications. The patient has since made a full recovery and returned home to his family.

    Hemopurifier is a registered, protected term of Aethlon Medical.

    Antivirals Ebola Emerging Threats
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – January 5, 2015
    Next Article NASA Seeks Compact Diagnostics for Space Missions

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Valley Fever: An Invisible Killer Expands Its Range in the American West

    November 17, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.